{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-059124","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.816229+00:00","generated_at":"2026-06-02T07:04:16.927049+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Century Therapeutics Q1 2024 net loss $28.1M; expands autoimmune plans","bullets":["Net loss of $28.1M for Q1 2024 vs $31.3M in Q1 2023; R&D expenses $23.4M, down from $24.9M.","Cash, cash equivalents and marketable securities $249.9M as of March 31, 2024; cash runway into 2026.","Closed $60M private placement led by Bain Capital Life Sciences in April 2024.","Plans additional regulatory filings for CNTY-101 in autoimmune diseases beyond SLE in H2 2024.","FY2024 GAAP operating expense guidance raised to $150-160M (prior $135-145M) due to Clade acquisition and expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-059124","json":"https://secwatch.observer/filing/0001104659-24-059124.json","markdown":"https://secwatch.observer/filing/0001104659-24-059124.md","text":"https://secwatch.observer/filing/0001104659-24-059124.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465924059124/0001104659-24-059124-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465924059124/tm2413916d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T07:04:16.927049+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f8852ac666310e69f8d86421474ceaab47a6539","claim":"Century Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune diseases, today reported financial results and business highlights for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850119/000110465924059124/0001104659-24-059124-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}